nsulin - Glucose – Diabetic - Diabetes Type 1 - Diabetes Type 2 – Insulin – Hypoglycemia -Hyperglycemia - Neuropathy - Prediabetes - Monitoring - Nutrition

Development of a New Measure for Assessing Insulin Delivery Device Satisfaction in Patients with Type 1 and Type 2 Diabetes

Authors:  Polonsky, WH., Fisher, L., Hessler, D., Edelman, SV.

Abstract

Background: Although many different types of insulin delivery devices are currently available, there is no well-accepted, validated method to assess patient satisfaction with these devices and their impact on quality of life and other patient-reported outcomes. To address this problem, we developed the Insulin Device Satisfaction Survey (IDSS) and herein describe its construction and validation. We then examine how key patient factors are associated with device satisfaction.

Materials and methods: Items were developed from interviews with adults with type 1 diabetes (T1D) (n=10) and type 2 diabetes (T2D) using insulin (n=10), as well as eight healthcare professionals, leading to an initial pool of 32 items. Separate exploratory factor analyses (EFAs) were conducted with T1D subjects (n=279) and insulin-using T2D subjects (n=209). Construct validity was established with overall well-being (World Health Organization-5), diabetes distress (Diabetes Distress Scale), diabetes self-efficacy (Self-Efficacy for Diabetes Management Scale), and subscales from the Insulin Delivery System Rating Questionnaire. Regression analyses examined associations between total scale satisfaction and demographics, insulin adherence, clinical indicators, and device type (pump vs. nonpump users).

Results: The two EFAs resulted in a 14-item scale for T1D subjects and a 12-item scale for T2D subjects, with eight items common across both samples. The EFAs yielded three coherent, meaningful factors in each sample, accounting for 55.6% (T1D sample) and 64.1% (T2D sample) of the variance. Validity was established by significant correlations with all criterion variables. For both samples, higher IDSS scores were significantly associated with better glycemic control and greater insulin adherence and pump use. For T2D subjects only, IDDS scores were significantly linked to fewer long-term complications, fewer low blood glucose readings, and older age.

Conclusions: The IDSS is a reliable, valid measure of insulin device satisfaction in both its T1D form and T2 form. It provides a comprehensive profile of sources of device satisfaction for use in clinical care and research.

Source: https://pubmed.ncbi.nlm.nih.gov/26167948/

Share the Post:

BDI Monthly Events

May 7OMEGA Conference
May 7: As a keynote speaker at OMEGA, the First International Conference on Once-Weekly Glycated Albumin Monitoring for Diabetes, Dr. Polonsky (BDI President) will be presenting on “Glucose Monitoring and Behavior Change” (Tokyo, Japan).
May 14Case Consultation
May 14: BDI hosts the San Diego-wide, monthly case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at [email protected] if you are in the greater San Diego area and would like further information about this program.
May 18T1D Meet Up
May 18: Time for another T1D meet-up! Our friends and colleagues at GrownupT1Ds, a wonderful nonprofit here in southern California, is organizing another fun social event for adults with type 1 diabetes. This time it is a Walk, Talk & Picnic, and it begins at 11 am at the Bommer Canyon Trail (1 Sunnyhill, Irvine, CA). 92084. This event is free, but please RSVP Kelly Daes at www.grownupt1ds.org.
May 23SITEC 2025
May 23: Dr. Polonsky will be presenting (virtually) on “Far Beyond Time in Range: Exploring the Promises and Limitations of CGM” at SITEC 2025, Innovation and Technology Transforming Diabetes Care (Sao Paolo, Brazil). https://sitec.diabetes.org.br/